Truist Securities Reiterates Buy on Immunovant, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a $30 price target.
August 16, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunovant's stock rating has been reiterated as 'Buy' by Truist Securities with a maintained price target of $30.
The reiteration of a 'Buy' rating by a reputable analyst like Robyn Karnauskas from Truist Securities is a positive signal for Immunovant. The maintained price target of $30 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100